Pharmaxis Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Pharmaxis Ltd with three other companies in this sector in AUSTRALIA : Immutep Ltd (2020 sales of 13.94 million Australian Dollars [US$10.76 million] of which 99% was Cancer Immunotherapy), Idt Australia Limited. (14.17 million Australian Dollars [US$10.94 million] ), and Cellmid Limited (7.48 million Australian Dollars [US$5.78 million] of which 79% was Advangen Japan).

Sales Analysis. During the year ended June of 2020, sales at Pharmaxis Ltd were A$12.55 million (US$9.69 million). This is a very small increase of 0.0% versus 2019, when the company's sales were A$12.55 million. Despite this increase, sales are still well below the level achieved in 2018, when Pharmaxis Ltd reported sales of A$50.33 million. Sales of Mannitol saw an increase that was more than double the company's growth rate: sales were up 23.6% in 2020, from A$5.70 million to A$7.05 million. Not all segments of Pharmaxis Ltd experienced an increase in sales in 2020: sales of New Drug Development fell 13.5% to A$5.16 million. Pharmaxis Ltd also experienced decreases in sales in Corporate (down 9.3% to A$459,000.00 ) .